Literature DB >> 17673575

The design and assessment of prospective randomised, controlled trials in orthopaedic surgery.

I Boutron1, P Ravaud, R Nizard.   

Abstract

Randomised controlled trials represent the gold standard in the evaluation of outcome of treatment. They are needed because differences between treatment effects have been minimised and observational studies may give a biased estimation of the outcome. However, conducting this kind of trial is challenging. Several methodological issues, including patient or surgeon preference, blinding, surgical standardisation, as well as external validity, have to be addressed in order to lower the risk of bias. Specific tools have been developed in order to take into account the specificity of evaluation of the literature on non-pharmacological intervention. A better knowledge of methodological issues will allow the orthopaedic surgeon to conduct more appropriate studies and to better appraise the limits of his intervention.

Entities:  

Mesh:

Year:  2007        PMID: 17673575     DOI: 10.1302/0301-620X.89B7.19440

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  10 in total

1.  Methodological and ethical quality of randomized controlled clinical trials in gastrointestinal surgery.

Authors:  Valérie Bridoux; Grégoire Moutel; Horace Roman; Babak Kianifard; Francis Michot; Christian Herve; Jean-Jacques Tuech
Journal:  J Gastrointest Surg       Date:  2012-07-10       Impact factor: 3.452

Review 2.  Development of appropriateness criteria for the surgical treatment of symptomatic lumbar degenerative spondylolisthesis (LDS).

Authors:  A F Mannion; V Pittet; F Steiger; J-P Vader; H-J Becker; F Porchet
Journal:  Eur Spine J       Date:  2014-04-24       Impact factor: 3.134

Review 3.  High-flexion total knee arthroplasty: a systematic review.

Authors:  Michael Murphy; Simon Journeaux; Trevor Russell
Journal:  Int Orthop       Date:  2009-04-08       Impact factor: 3.075

4.  A statistical framework for quantifying clinical equipoise for individual cases during randomized controlled surgical trials.

Authors:  Nicholas R Parsons; Yuri Kulikov; Alan Girling; Damian Griffin
Journal:  Trials       Date:  2011-12-13       Impact factor: 2.279

5.  Improving site selection in clinical studies: a standardised, objective, multistep method and first experience results.

Authors:  Anahí Hurtado-Chong; Alexander Joeris; Denise Hess; Michael Blauth
Journal:  BMJ Open       Date:  2017-07-12       Impact factor: 2.692

6.  Quality of reporting of systematic reviews and meta-analyses of surgical randomized clinical trials.

Authors:  J Yu; W Chen; P Wu; Y Li
Journal:  BJS Open       Date:  2020-02-28

7.  How good is the orthopaedic literature?

Authors:  Harman Chaudhry; Raman Mundi; Ishu Singh; Thomas A Einhorn; Mohit Bhandari
Journal:  Indian J Orthop       Date:  2008-04       Impact factor: 1.251

8.  Finnish Degenerative Meniscal Lesion Study (FIDELITY): a protocol for a randomised, placebo surgery controlled trial on the efficacy of arthroscopic partial meniscectomy for patients with degenerative meniscus injury with a novel 'RCT within-a-cohort' study design.

Authors:  Raine Sihvonen; Mika Paavola; Antti Malmivaara; Teppo L N Järvinen
Journal:  BMJ Open       Date:  2013-03-09       Impact factor: 2.692

9.  Curved versus Straight Stem Uncemented Total Hip Arthroplasty Osteoarthritis Multicenter trial (CUSTOM): design of a prospective blinded randomised controlled multicentre trial.

Authors:  Loes W A H van Beers; Jakob van Oldenrijk; Vanessa A B Scholtes; Carel H Geerdink; Bob B A M Niers; Wouter Runne; Mohit Bhandari; Rudolf W Poolman
Journal:  BMJ Open       Date:  2016-03-23       Impact factor: 2.692

10.  Trials based on specific fracture configuration and surgical procedures likely to be more relevant for decision making in the management of fractures of the proximal humerus: Findings of a meta-analysis.

Authors:  S Sabharwal; N K Patel; D Griffiths; T Athanasiou; C M Gupte; P Reilly
Journal:  Bone Joint Res       Date:  2016-10       Impact factor: 5.853

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.